Nuvalent, Inc.

Nuvalent, Inc.

NUVLNYSE / NASDAQHealthcareSmall cap

$123.96$0.00 (0.0%)

Last close · Data as of Jul 21, 2026

Market cap
$7.4B
P/E
-17.5x
Revenue
$0.00
ROCE
-31.4%

Hidden because the last close is more than three trading days older than the latest prices of its class.

Nuvalent, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 21 Jul 2026 close.

1M
Stale
3M
Stale
6M
Stale
1Y
Stale
5Y
Stale
  • Hidden because the last close is more than three trading days older than the latest prices of its class.

52-week range

Day change $0.00 (0.0%) from $124 to $124 · Last close Jul 21, 2026

Best weekday to invest, historically

The same weekly amount in NUVL, bought on each weekday since 2021.

News & filings

What Nuvalent filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 425 million US dollars in fiscal 2025.

Strengths (1)

  • Current assets are more than ten times current liabilities.
  • Prices are as of 21 Jul 2026; price-based points are paused until newer prices arrive.
  • Revenue is too small for margins and growth rates to be read, so those points are not shown.

Prices to the 21 Jul 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Nuvalent, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer.

Read moreShow less

Nuvalent, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are Zidesamtinib (NVL-520), a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the Phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; Neladalkib (NVL-655), a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the Phase 2 portion of the ALKOVE-1 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR that is in Phase 1a/1b clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Sector
Healthcare
Shares outstanding
78.2M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$7.4B
P/E
-17.5x
P/B
5.9x
52-week high
$123.96
52-week low
$72.16

Profitability

ROE
-34.1%
ROCE
-31.4%
ROIC
-33.2%
ROA
-30.1%

Growth

Revenue
$0.00
Net profit growth, 1Y
63.1%
Free cash flow
-$275.2M

Solvency

Current ratio
15.27
Debt / Equity
0.00
Debt / Assets
0.00
CFO / Net profit
0.65
Cash / Market cap
3.5%

Revenue and net profit

Annual revenue, with net profit as the dashed line.

Nuvalent, Inc. revenue and net profit by fiscal year
Nuvalent, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$0.00-$81.9M
FY2023$0.00-$126.2M
FY2024$0.00-$260.8M
FY2025$0.00-$425.4M

Cash flows

FY2025: -$275.2M from operations, -$275.2M free after investment (dashed).

Nuvalent, Inc. operating and free cash flow by fiscal year
Nuvalent, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$65.0M-$65.0M
FY2023-$99.7M-$99.7M
FY2024-$185.1M-$185.1M
FY2025-$275.2M-$275.2M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$0.00
EBITDA
-$414.3M
Net profit
-$425.4M
Cash from operations
-$275.2M
Free cash flow
-$275.2M
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$0.00-$414.3M-$425.4M-$275.2M-34.1%—+63.1%

Monthly returns

Month-by-month returns of NUVL across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$1.4B
Liabilities$164.4M
Equity$1.2B
Paid-in capital$2.2B
Retained earnings-$972.4M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; NUVL highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

EV / Sales, for the companies without earnings

Not shown (no positive earnings and no EV / Sales): Nuvalent, Inc., Praxis Precision Medicines, Inc., Vaxcyte, Inc., Apogee Therapeutics, Inc., Spyre Therapeutics, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Nuvalent, Inc.NUVLthis company$7.4B-17.5x5.9x-34.1%—
ImmunityBio, Inc.IBRX$7.6B-21.7x-15.3x70.2%-36.1x
Praxis Precision Medicines, Inc.PRAX$7.4B-24.3x8.4x-34.5%-21.5x
HealthEquity, Inc.HQY$7.2B33.4x3.4x10.2%16.1x
Oscar Health, Inc.OSCR$7.1B-16.1x7.3x-45.3%—
Vaxcyte, Inc.PCVX$7.0B-9.2x2.6x-28.5%-7.8x
Apogee Therapeutics, Inc.APGE$6.9B-26.8x7.6x-28.3%-23.7x
Spyre Therapeutics, Inc.SYRE$6.8B—9.5x-21.7%—
Arcellx, Inc.ACLX$6.7B-29.4x16.7x-56.9%-30.2x
Peer median—-21.7x7.4x-28.4%-22.6x

Year-to-date ROI

NUVL since 1 January, against earlier years.

Historical volatility

NUVL's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

LineFY2025
Operating expensesOperating Expense$414.3M
Research and developmentResearch And Development$307.0M
Insurance and claimsInsurance And Claims$28.6M
Total expensesTotal Expenses$414.3M
Pretax incomePretax Income-$424.8M

Learn while you research

Academy chapters picked for Nuvalent, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  3. 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →